HRP950483B1 - New pharmaceutical product - Google Patents

New pharmaceutical product

Info

Publication number
HRP950483B1
HRP950483B1 HR950483A HRP950483A HRP950483B1 HR P950483 B1 HRP950483 B1 HR P950483B1 HR 950483 A HR950483 A HR 950483A HR P950483 A HRP950483 A HR P950483A HR P950483 B1 HRP950483 B1 HR P950483B1
Authority
HR
Croatia
Prior art keywords
pharmaceutical product
new pharmaceutical
new
product
pharmaceutical
Prior art date
Application number
HR950483A
Other languages
English (en)
Inventor
Elizabeth Smith Labell
Wayne Douglas Luke
John Mcneill Mcgill Iii
Randal Scot Miller
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26976194&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP950483(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/308,325 external-priority patent/US5629425A/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HRP950483A2 publication Critical patent/HRP950483A2/hr
Publication of HRP950483B1 publication Critical patent/HRP950483B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
HR950483A 1994-09-19 1995-09-18 New pharmaceutical product HRP950483B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/308,325 US5629425A (en) 1994-09-19 1994-09-19 Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene
US42791495A 1995-04-26 1995-04-26

Publications (2)

Publication Number Publication Date
HRP950483A2 HRP950483A2 (en) 1997-10-31
HRP950483B1 true HRP950483B1 (en) 2003-02-28

Family

ID=26976194

Family Applications (2)

Application Number Title Priority Date Filing Date
HR950482A HRP950482B1 (en) 1994-09-19 1995-09-18 SYNTHESIS OF 3-(4-(2-AMINOETOXY)BENZOYL)-ARYL-6-HYDROXYBENZO(b)THIOPHENE
HR950483A HRP950483B1 (en) 1994-09-19 1995-09-18 New pharmaceutical product

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HR950482A HRP950482B1 (en) 1994-09-19 1995-09-18 SYNTHESIS OF 3-(4-(2-AMINOETOXY)BENZOYL)-ARYL-6-HYDROXYBENZO(b)THIOPHENE

Country Status (51)

Country Link
US (4) US6399778B1 (et)
JP (2) JPH08193081A (et)
KR (2) KR100367376B1 (et)
CN (2) CN1068324C (et)
AP (1) AP754A (et)
AT (2) AT407988B (et)
AU (3) AU692907B2 (et)
BE (2) BE1009626A3 (et)
BG (1) BG62793B1 (et)
BR (2) BR9504059A (et)
CA (2) CA2158400C (et)
CH (3) CH691594A5 (et)
CO (2) CO4410190A1 (et)
CZ (2) CZ292007B6 (et)
DE (3) DE19534744A1 (et)
DK (4) DK175897B1 (et)
EE (1) EE03386B1 (et)
EG (1) EG23763A (et)
ES (2) ES2109882B1 (et)
FI (2) FI112226B (et)
FR (2) FR2732020B1 (et)
GB (2) GB2293382B (et)
GE (1) GEP19991821B (et)
GR (2) GR1002709B (et)
HK (1) HK1019009A1 (et)
HR (2) HRP950482B1 (et)
HU (2) HU227683B1 (et)
IE (2) IE80883B1 (et)
IL (3) IL125283A (et)
IS (1) IS1788B (et)
IT (2) IT1277602B1 (et)
LU (2) LU88661A1 (et)
LV (2) LV11178B (et)
MY (1) MY116371A (et)
NL (2) NL1001194C2 (et)
NO (2) NO308107B1 (et)
NZ (2) NZ280027A (et)
OA (1) OA10406A (et)
PE (2) PE14796A1 (et)
PL (2) PL182450B1 (et)
PT (2) PT101771B (et)
RO (2) RO115259B1 (et)
RS (2) RS49578B (et)
SE (2) SE520721C2 (et)
SI (2) SI9500293A (et)
SK (1) SK283502B6 (et)
TR (1) TR199501136A2 (et)
TW (1) TW412534B (et)
UA (2) UA44240C2 (et)
UY (1) UY24040A1 (et)
WO (1) WO1996009045A1 (et)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39049E1 (en) 1992-07-28 2006-03-28 Eli Lilly And Company Methods for inhibiting bone loss
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
USRE38968E1 (en) 1992-07-28 2006-02-07 Eli Lilly And Company Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
CO4410190A1 (es) * 1994-09-19 1997-01-09 Lilly Co Eli 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO
CZ300341B6 (cs) * 1996-03-26 2009-04-22 Eli Lilly And Company Farmaceutická kompozice obsahující raloxifen
US6458811B1 (en) * 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
ZA992858B (en) 1996-10-30 1999-07-29 Lilly Co Eli Methods of preventing breast cancer.
CA2236254A1 (en) * 1997-04-30 1998-10-30 David Warren Hoard Process for preparing benzo¬b|thiophenes
DK1175433T3 (da) 1999-05-04 2005-09-19 Strakan Int Ltd Androgenglycosider og androgen aktivitet deraf
WO2003079972A2 (en) 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
AU2002230409A1 (en) * 2000-11-27 2002-06-03 Eli Lilly And Company Process for preparing 3-aryl-benzo(b)thiophenes
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
AU2003266940B2 (en) 2002-09-30 2007-02-08 A/S Gea Farmaceutisk Fabrik Novel raloxifene acid addition salts and/or solvates thereof, improved method for purification of said raloxifene acid addition salts and/or solvates thereof and pharmaceutical compositions comprising these
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US20060106010A1 (en) * 2003-05-27 2006-05-18 Black Larry J Methods for inhibiting bone loss
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
KR20090018224A (ko) 2004-09-29 2009-02-19 바이엘 헬스케어 아게 열역학적으로 안정한 형태의 ｂａｙ 43-9006 토실레이트
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
NZ573360A (en) 2006-05-04 2012-08-31 Boehringer Ingelheim Int Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
KR20090082399A (ko) * 2006-10-17 2009-07-30 씨아이피엘에이 엘티디. 벤조티오펜 화합물의 결정형 및 그의 제조방법
US20080103295A1 (en) * 2006-10-25 2008-05-01 David Losan Ho Process for the preparation of sucrose-6-ester by esterification in the presence of solid superacid catalyst
US8258291B2 (en) * 2006-10-25 2012-09-04 Mamtek International Limited Process for the preparation of sucralose by the chlorination of sugar with triphosgene (BTC)
DE102007032451B4 (de) 2007-07-12 2010-09-30 Icfs Gmbh Verfahren zur Herstellung von aromatischen Ketonen
US20090023799A1 (en) * 2007-07-20 2009-01-22 George Laurence CRYSTALS OF (2-AMINO-4,5,6,7-TETRAHYDROBENZO[b]THIEN-3-YL)(4-CHLOROPHENYL)METHANONE
WO2009019205A1 (en) 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Crystalline form of a dihydropteridione derivative
WO2009080364A1 (en) * 2007-12-21 2009-07-02 Synthon B.V. Raloxifene composition
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
US20110088613A1 (en) * 2008-06-09 2011-04-21 Massimo Ferrari Process for controlling the growth of a raloxifene hydrochloride crystal
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
JP2012502081A (ja) 2008-09-10 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連症状の治療のための組み合わせ治療
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
TWI508965B (zh) 2008-12-23 2015-11-21 Boehringer Ingelheim Int 有機化合物的鹽形式
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
ES2437916T3 (es) 2009-07-02 2014-01-15 Synthon B.V. Composición de raloxifeno
EP2314581B1 (en) 2009-10-23 2012-07-25 Hexal AG A process for preparing benzo[b]thiophene derivatives
JP2013512229A (ja) 2009-11-27 2013-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 遺伝子型が同定された糖尿病患者のリナグリプチン等のｄｄｐ−ｉｖ阻害薬による治療
WO2011099942A1 (en) 2010-02-09 2011-08-18 Silverstone Pharma New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy
NZ602921A (en) 2010-05-05 2016-01-29 Boehringer Ingelheim Int Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor
MX2012014247A (es) 2010-06-24 2013-01-18 Boehringer Ingelheim Int Terapia para la diabetes.
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
IT1403083B1 (it) * 2010-10-25 2013-10-04 Fidia Farmaceutici Nuova forma polimorfa di raloxifene cloridrato
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ZA201401636B (en) 2013-03-05 2014-11-26 Cipla Ltd Oxalic acid addition salts and/or solvates of a selective estrogen receptor modulator
US20150031699A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
CN104496963A (zh) * 2014-12-02 2015-04-08 千辉药业（安徽）有限责任公司 一种盐酸雷洛昔芬的制备方法
EP3468562A1 (en) 2016-06-10 2019-04-17 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3869485A (en) * 1969-09-25 1975-03-04 Allied Chem Preparation of acid chlorides with phosgene in the presence of a catalyst
GB1456323A (en) * 1974-06-06 1976-11-24 Labaz Benzothiophenes process for preparing them and pharmaceutical compositions containing the same
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
IL65378A (en) * 1981-04-03 1986-02-28 Lilly Co Eli Process for preparing 3-(4-aminoethoxybenzoyl)benzo-(b)thiophenes
ZA822247B (en) 1981-04-03 1983-11-30 Lilly Co Eli Benzothiophene compounds and process for preparing them
US4380635A (en) 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
IL65379A0 (en) * 1981-04-03 1982-05-31 Lilly Co Eli Process for preparing acylated benzothiophenes
US4358593A (en) * 1981-04-03 1982-11-09 Eli Lilly And Company Process for preparing 3-(4-aminoethoxybenzoyl)benzo[b]thiophenes
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
EP0062503A1 (en) * 1981-04-03 1982-10-13 Eli Lilly And Company Benzothiophene compounds and process for preparing them
DE4117512A1 (de) 1991-05-25 1992-11-26 Schering Ag 2-phenylbenzo(b)furane und -thiophene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US5169860A (en) * 1992-03-13 1992-12-08 Eli Lilly And Company Antitumor compositions and methods of treatment
TW383306B (en) * 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
IL110052A (en) 1993-06-24 2001-04-30 Lilly Co Eli Pharmaceutical preparations containing derivatives of benzothiophene used as hypoglycemic compounds
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5523416A (en) 1994-07-22 1996-06-04 Eli Lilly And Company Process for preparing 3-(4-aminoethoxy-benzoyl) benzo (B)-thiophenes
CO4410190A1 (es) * 1994-09-19 1997-01-09 Lilly Co Eli 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO

Also Published As

Publication number Publication date
LV11178B (en) 1996-08-20
SK23397A3 (en) 1997-08-06
PL187686B1 (pl) 2004-09-30
TR199501136A2 (tr) 1996-06-21
FR2732020A1 (fr) 1996-09-27
AU3718695A (en) 1996-04-09
CA2158399C (en) 2001-03-20
PL182450B1 (pl) 2002-01-31
JP2860071B2 (ja) 1999-02-24
ATA154295A (de) 2000-12-15
BG62793B1 (bg) 2000-08-31
GR1002709B (el) 1997-06-04
ES2109882B1 (es) 1998-08-16
BG101242A (en) 1998-03-31
EG23763A (en) 2007-08-08
IS1788B (is) 2001-11-28
LU88661A1 (fr) 1996-07-15
GB2293602A (en) 1996-04-03
AT407988B (de) 2001-07-25
DK175903B1 (da) 2005-06-06
US6472531B1 (en) 2002-10-29
KR960010634A (ko) 1996-04-20
CN1132205A (zh) 1996-10-02
ES2129293B1 (es) 2000-01-16
DK2897A (da) 1997-01-09
CZ292007B6 (cs) 2003-07-16
ITMI951936A0 (it) 1995-09-15
RS49513B (sr) 2006-10-27
NZ280028A (en) 1997-05-26
FI121424B (fi) 2010-11-15
DK102895A (da) 1996-03-20
CN1068324C (zh) 2001-07-11
PT101771B (pt) 1997-04-30
NO953658D0 (no) 1995-09-15
DK175886B1 (da) 2005-05-23
HRP950482B1 (en) 2007-04-30
IE80883B1 (en) 1999-05-19
KR960010637A (ko) 1996-04-20
DK175887B1 (da) 2005-05-23
NZ280027A (en) 1997-05-26
NL1001196C2 (nl) 1997-04-04
NL1001196A1 (nl) 1996-03-19
AU692907B2 (en) 1998-06-18
GEP19991821B (en) 1999-11-05
AP9700938A0 (en) 1997-04-30
IL115315A (en) 1999-09-22
SE9503213D0 (sv) 1995-09-15
HUT75033A (en) 1997-03-28
US20020173645A1 (en) 2002-11-21
SE520721C2 (sv) 2003-08-12
AT502957A1 (de) 2007-06-15
KR100381346B1 (ko) 2004-04-13
IS4446A (is) 1997-03-18
CO4410190A1 (es) 1997-01-09
CZ240295A3 (en) 1996-04-17
AU3173195A (en) 1996-04-04
GB2293382A (en) 1996-03-27
GB2293382B (en) 1998-08-19
UA42716C2 (uk) 2001-11-15
RO115260B1 (ro) 1999-12-30
HUT74178A (en) 1996-11-28
SI9500292A (en) 1996-06-30
CA2158400A1 (en) 1996-03-20
LV11177B (en) 1996-08-20
ITMI951935A0 (it) 1995-09-15
ES2109882A1 (es) 1998-01-16
SE509265C2 (sv) 1998-12-21
DE19534745A1 (de) 1996-04-04
NL1001194C2 (nl) 1997-04-04
CN1075069C (zh) 2001-11-21
IT1277602B1 (it) 1997-11-11
US5731327A (en) 1998-03-24
UY24040A1 (es) 1996-03-07
FI112226B (fi) 2003-11-14
FI954402A0 (fi) 1995-09-18
BE1009626A3 (fr) 1997-06-03
SE9503213L (sv) 1996-03-20
FI954403A (fi) 1996-03-20
HU227683B1 (en) 2011-11-28
HU9502721D0 (en) 1995-11-28
DE19549755B4 (de) 2005-05-04
BR9504059A (pt) 1996-09-24
HU9502723D0 (en) 1995-11-28
BR9504060A (pt) 1996-09-24
IL115315A0 (en) 1995-12-31
CA2158399A1 (en) 1996-03-20
HRP950483A2 (en) 1997-10-31
GB2293602B (en) 1998-05-06
CH691478A5 (de) 2001-07-31
FR2724655A1 (fr) 1996-03-22
DK102795A (da) 1996-03-20
OA10406A (en) 2001-12-05
HU225417B1 (en) 2006-11-28
ES2129293A1 (es) 1999-06-01
SK283502B6 (sk) 2003-08-05
MY116371A (en) 2004-01-31
JPH08176147A (ja) 1996-07-09
FR2724655B1 (fr) 1997-11-14
HRP950482A2 (en) 1998-02-28
IE950721A1 (en) 1996-03-20
RS49578B (sr) 2007-04-10
PE14796A1 (es) 1996-05-19
NL1001194A1 (nl) 1996-03-19
YU61395A (sh) 1998-09-18
ITMI951936A1 (it) 1997-03-15
PL310518A1 (en) 1996-04-01
EE03386B1 (et) 2001-04-16
WO1996009045A1 (en) 1996-03-28
LV11177A (lv) 1996-04-20
LV11178A (lv) 1996-04-20
NO313996B1 (no) 2003-01-13
CN1127253A (zh) 1996-07-24
YU61495A (sh) 1998-05-15
FR2732020B1 (fr) 1997-11-14
HK1019009A1 (en) 2000-01-14
PT101770A (pt) 1996-04-30
NO953657D0 (no) 1995-09-15
PL310517A1 (en) 1996-04-01
PT101771A (pt) 1996-04-30
AU691955B2 (en) 1998-05-28
GB9519028D0 (en) 1995-11-15
LU88660A1 (fr) 1996-07-15
AU3173095A (en) 1996-04-04
DE19534745B4 (de) 2004-06-09
IE950722A1 (en) 1996-03-20
IL115314A0 (en) 1996-05-14
DE19534744A1 (de) 1996-03-21
UA44240C2 (uk) 2002-02-15
IT1277601B1 (it) 1997-11-11
US6399778B1 (en) 2002-06-04
CZ240395A3 (en) 1996-04-17
GR1002697B (el) 1997-05-22
CZ290343B6 (cs) 2002-07-17
EE9700055A (et) 1997-08-15
JPH08193081A (ja) 1996-07-30
CH691125A5 (de) 2001-04-30
DK2797A (da) 1997-01-09
FI954402A (fi) 1996-03-20
IL115314A (en) 2000-02-29
NO953657L (no) 1996-03-20
CA2158400C (en) 2006-10-24
NO953658L (no) 1996-03-20
SE9503214D0 (sv) 1995-09-15
NO308107B1 (no) 2000-07-24
DK175897B1 (da) 2005-05-30
SE9503214L (sv) 1996-03-20
ITMI951935A1 (it) 1997-03-15
TW412534B (en) 2000-11-21
AP754A (en) 1999-07-22
RO115259B1 (ro) 1999-12-30
BE1009625A3 (fr) 1997-06-03
PT101770B (pt) 1997-04-30
KR100367376B1 (ko) 2003-03-06
SI9500293A (en) 1996-06-30
GB9519032D0 (en) 1995-11-15
IL125283A (en) 2001-06-14
CH691594A5 (de) 2001-08-31
FI954403A0 (fi) 1995-09-18
CO4410191A1 (es) 1997-01-09
PE32796A1 (es) 1996-08-07

Similar Documents

Publication Publication Date Title
HRP950483B1 (en) New pharmaceutical product
GB9402807D0 (en) Pharmaceutical compounds
ZA957753B (en) Novel pharmaceutical product
GB9610862D0 (en) Pharmaceutical products
GB9410387D0 (en) Pharmaceutical compounds
GB2286394B (en) Pharmaceutical compounds
ZA948506B (en) Pharmaceutical product
GB9619894D0 (en) Pharmaceutical products
ZA95704B (en) A pharmaceutical product
ZA95703B (en) A pharmaceutical product
AU126984S (en) Pharmaceutical product
GB9402805D0 (en) Pharmaceutical compounds
GB9413859D0 (en) Pharmaceutical products
SG32504A1 (en) Novel pharmaceutical product
GB9612684D0 (en) Pharmaceutical products
ZA968431B (en) Pharmaceutical product
GB9405248D0 (en) Novel pharmaceutical
GB9418070D0 (en) Product
GB9505852D0 (en) General product
GB9402589D0 (en) Pharmaceutical process
GB9620834D0 (en) Pharmaceutical products
GB9620465D0 (en) Pharmaceutical products
GB9402409D0 (en) Novel pharmaceutical use
GB9421156D0 (en) New pharmaceutical use
GB9405195D0 (en) New pharmaceutical use

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20130917

Year of fee payment: 19

PBON Lapse due to non-payment of renewal fee

Effective date: 20150918